Back to news and articles

Animals & planet

FDA outlines a plan to reduce animal testing for certain medicines

The April 2025 announcement described a gradual move towards validated alternatives, initially focusing on monoclonal antibodies and other medicines.

FacebookX

FDA outlines a plan to reduce animal testing for certain medicines

The US Food and Drug Administration (FDA) announced a plan to phase out some animal-testing requirements in the development of monoclonal antibody therapies and other medicines. The agency described the initiative as a step towards advancing public health. (FDA — 2025)

The plan calls for greater use of methods relevant to human biology, including AI-based computational models of toxicity, cell cultures and laboratory-grown organoid models.

For medicines with existing human-use experience, the FDA said real-world safety data from other countries with comparable regulatory standards could also be considered. It encouraged the submission of non-animal data in investigational new drug (IND) applications.

The agency’s stated aims included improving safety assessment, speeding up evaluation, reducing animal use and lowering research and development costs. These were policy objectives, rather than guaranteed outcomes for every medicine.

The FDA said it would update guidance on evaluating data from these methods. It also described possible regulatory incentives for companies providing robust safety evidence from non-animal approaches.

A new approach to drug evaluation

The plan described reducing, refining and potentially replacing animal-testing requirements. The FDA proposed working with agencies including the National Institutes of Health (NIH), the National Toxicology Program (NTP) and the Department of Veterans Affairs, through the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM).

The April 2025 announcement also outlined a pilot involving selected monoclonal-antibody developers, with findings intended to inform wider policy changes. A public workshop with federal partners was planned for later in 2025. These are the plans described at the time of the announcement.

FDA Commissioner Dr Martin A. Makary said:

Makary argued that drug developers had long been required to repeat animal studies even for medicines already used widely abroad. He presented the initiative as a different approach to evaluation, intended to accelerate the development of treatments while reducing animal use.

He also highlighted computational models, human organoid systems and real-world human data as tools the agency hoped would improve evaluation and reduce development costs. His remarks expressed the agency’s intended benefits, rather than established results of the new programme.

Sources